AbbVie Quietly Solved Its Biggest Problem—Now What?
AbbVie has moved beyond its Humira dependence, with diversified growth, a strong pipeline, and a reliable dividend supporting its next leg higher. Could the Apogee acquisition and sustained institutional backing propel ABBV toward $300?